0.50Open0.50Pre Close0 Volume18 Open Interest0.50Strike Price0.00Turnover729.43%IV8.70%PremiumDec 20, 2024Expiry Date0.42Intrinsic Value100Multiplier5DDays to Expiry0.08Extrinsic Value100Contract SizeAmericanOptions Type0.8721Delta0.2613Gamma1.84Leverage Ratio-0.0167Theta0.0000Rho1.60Eff Leverage0.0002Vega
Assertio Stock Discussion
Assertio Announces Results of Rolvedon® (eflapegrastim-xnst) injection Same-Day Dosing Clinical Study
Friday, 13th December at 8:00 am
LAKE FOREST, Ill., Dec. 13, 2024 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. ("Assertio" or the "Company") (NASDAQ: ASRT), a pharmaceutical company with comprehensive commercial capabilities offering differentiated products to patients, announced yesterday results of a clinical trial investigating the utility of Rolvedon® (eflapegrastim-x...
Underated/Valued, overlooked, great buy!!!
This one is killin it....
No comment yet